Chas Mckhann Biography and Net Worth

CEO of Apollo Endosurgery

Charles (Chas) McKhann was named President & Chief Executive Officer and a member of the Board of Directors in March 2021. Mr. McKhann has served in Chief Executive Officer or Chief Commercial Officer roles in four medical device companies including Torax Medical (acquired by J&J) and Intersect ENT (ticker: XENT). Previously, Mr. McKhann served in leadership roles at Boston Scientific Corporation and at Cordis, a Johnson & Johnson company. Earlier in his career, Mr. McKhann was a strategy consultant at McKinsey & Company. Mr. McKhann holds a Bachelor’s degree and Masters of Business Administration from Stanford University.

What is Chas Mckhann's net worth?: The estimated net worth of Chas Mckhann is at least $0.00 as of August 18th, 2021. Mckhann owns 686,122 shares of Apollo Endosurgery stock worth more than $0 as of April 24th. This net worth evaluation does not reflect any other investments that Mckhann may own. Learn More about Chas Mckhann's net worth.
How do I contact Chas Mckhann?: The corporate mailing address for Mckhann and other Apollo Endosurgery executives is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. Apollo Endosurgery can also be reached via phone at (512) 279-5100 and via email at [email protected]. Learn More on Chas Mckhann's contact information.
Has Chas Mckhann been buying or selling shares of Apollo Endosurgery?: Chas Mckhann has not been actively trading shares of Apollo Endosurgery in the last ninety days. Most recently, Chas Mckhann sold 21,148 shares of the business's stock in a transaction on Friday, August 20th. The shares were sold at an average price of $7.74, for a transaction totalling $163,685.52. Learn More on Chas Mckhann's trading history.
Who are Apollo Endosurgery's active insiders?: Apollo Endosurgery's insider roster includes John Barr (Director), Jeffrey Black (CFO), Neil Gagnon (Major Shareholder), Chas Mckhann (CEO), and David Pacitti (Director). Learn More on Apollo Endosurgery's active insiders.

Chas Mckhann Insider Trading History at Apollo Endosurgery

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/20/2021	Sell	21,148	$7.74	$163,685.52
8/18/2021	Sell	21,156	$8.21	$173,690.76	686,122

Chas Mckhann Buying and Selling Activity at Apollo Endosurgery

Apollo Endosurgery Company Overview

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

Today's Range

Now: N/A

50 Day Range

MA: $9.94

$9.87

$10.00

2 Week Range

Now: N/A

Volume

1,658,800 shs

Average Volume

1,432,125 shs

Market Capitalization

$579.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.31

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

Click here now for the full details of this stock that’s set to rocket in the AI revolution…